Spero Therapeutics Financials

Earnings View

Profitability View

Liquidity View

Fundamentals View

Competition View

Spero Therapeutics Stock Summary

Spero Therapeutics competes with Assembly Biosciences, Achilles Therapeutics, Instil Bio, CytomX Therapeutics, and NextCure. Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant bacterial infections and rare diseases in the United States. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts. Spero Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 41 people.

Spero Therapeutics Key Financial Ratios

Spero Therapeutics Key Balance Sheet Accounts

Spero Therapeutics Key Income Statement Accounts

Spero Therapeutics Key Cash Accounts

Spero Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Spero Therapeutics's current stock value. Our valuation model uses many indicators to compare Spero Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Spero Therapeutics competition to find correlations between indicators driving Spero Therapeutics's intrinsic value. More Info.Spero Therapeutics is currently regarded as top stock in return on equity category among its peers. It also is currently regarded as top stock in return on asset category among its peers reporting about  0.41  of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Spero Therapeutics is roughly  2.46 . At this time, Spero Therapeutics' Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Spero Therapeutics' earnings, one of the primary drivers of an investment's value.

Spero Therapeutics Systematic Risk

Today, most investors in Spero Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Spero Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Spero Therapeutics growth as a starting point in their analysis.

Along with financial statement analysis, the daily predictive indicators of Spero Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Spero Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Spero Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Spero Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Spero Therapeutics's daily price indicators and compare them against related drivers.

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Spero Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Spero Stock, please use our How to Invest in Spero Therapeutics guide.You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Spero Therapeutics. If investors know Spero will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Spero Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Spero Therapeutics is measured differently than its book value, which is the value of Spero that is recorded on the company's balance sheet. Investors also form their own opinion of Spero Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Spero Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Spero Therapeutics' market value can be influenced by many factors that don't directly affect Spero Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Spero Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Spero Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Spero Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.